IND Readiness Becomes the Critical Milestone for Preclinical Biotech

Preclinical biotech companies are being judged more closely on their ability to move from discovery research into IND-enabling development. The transition is one of the most important points in the life of an early biotech because it determines whether a program is ready to be tested in humans.

The FDA’s Investigational New Drug application process includes legal requirements, internal review principles and a pre-IND consultation program that allows sponsors to communicate with review divisions before submission. The agency says the pre-IND program is designed to guide sponsors on the data needed to support an IND.

This makes regulatory planning essential for preclinical companies. A promising candidate must be supported by pharmacology, toxicology, manufacturing and study design evidence. If these elements are weak or poorly sequenced, the company can face delays that consume capital and weaken investor confidence.

FDA guidance on pharmacology and toxicology information says IND sponsors must describe study results and identify the qualifications of the individuals who evaluated the results and concluded that it is reasonably safe to begin proposed human investigations. This requirement shows why documentation and expert review matter as much as the experiments themselves.

The IND-enabling package is not generic. A small molecule, antibody, cell therapy or gene therapy may require different studies and manufacturing controls. The planned clinical trial also matters. A first-in-human oncology study may raise different questions than a chronic disease trial in healthier participants.

Preclinical biotech companies must therefore build a development strategy early. They need to decide which animal models are relevant, which safety endpoints matter and what manufacturing information must be ready before submission. Waiting until the end of discovery to think about IND requirements can create expensive rework.

Outsourcing is becoming part of this transition. The preclinical CRO market is growing as biotechs turn to external partners for bioanalysis, DMPK, toxicology and model-based studies. The Business Research Company says the global preclinical CRO market is expected to grow from USD 6.25 billion in 2025 to USD 6.84 billion in 2026, reflecting rising development complexity and increased R&D investment.

This does not make the sponsor’s responsibility disappear. A CRO can run studies, but the biotech company must own the development logic and ensure that the data package answers regulatory questions. Vendor coordination, protocol design and quality oversight remain critical.

The next phase of preclinical biotech development will likely favor teams that treat IND readiness as a company-building discipline. Scientific creativity must be paired with regulatory structure.

Preclinical biotech companies are becoming more milestone-driven. Their strongest value will come from showing that a candidate can move from compelling biology to a credible human testing plan.